Neural Tube Defects
1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
BayerDrospirenone/Ethinylestradiol/Methyltetrahydrofolate
GenomicsGenetics of Neural Tube Defects
Clinical Trials (2)
Total enrollment: 6,385 patients across 2 trials
Efficacy and Safety Study for an Oral Contraceptive Containing Folate
Start: Apr 2007Est. completion: Sep 2008385 patients
Phase 3Completed
Genetics of Neural Tube Defects
Start: Apr 20096,000 patients
N/AUnknown
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
2 companies competing in this space